Evidence map›Paper›PMID 36304124›Full record

ArticleiScience2022

Increased

Esteban M Lucero, Ronald K Freund, Alexandra Smith, Noah R Johnson, Breanna Dooling, Emily Sullivan, Olga Prikhodko, Md Mahiuddin Ahmed, David A Bennett, Timothy J Hohman and 3 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Research progress of kinesin family in neurological diseases.Frontiers in cellular neuroscience · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Esteban M LuceroDepartment of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Ronald K FreundUniversity of Colorado Alzheimer's and Cognition Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Alexandra SmithVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Noah R JohnsonDepartment of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Breanna DoolingDepartment of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Emily SullivanDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Olga PrikhodkoDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Md Mahiuddin AhmedDepartment of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Timothy J HohmanVanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Mark L Dell'AcquaUniversity of Colorado Alzheimer's and Cognition Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Heidi J ChialDepartment of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Huntington PotterDepartment of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
University of Colorado Anschutz Medical Campus · USVanderbilt University Medical Center · USRush University Medical Center · US

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI GLOVER, CRYSTAL M · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7M
Neuroprotective Effects of Vascular Endothelial Growth Factor in Alzheimer's DiseaseR01AG061518 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Timothy J Hohman · 2019 to 2026
$5.9M
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunctionR01NS110383 · NINDS · UNIVERSITY OF COLORADO DENVER · PI MARK L DELL'ACQUA, Matthew J Kennedy · 2018 to 2026
$5.2M
Genetic Drivers of Resilience to Alzheimer's DiseaseR01AG059716 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HOHMAN, TIMOTHY J · 2018 to 2022
$4.4M
Genetic Resilience to the Clinical Manifestation of DementiaK01AG049164 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HOHMAN, TIMOTHY J · 2016 to 2020
$595k
Calcineurin activation and scaffolding in A Beta-induced synaptic dysfunctionF32AG071073 · NIA · UNIVERSITY OF COLORADO DENVER · PI PRIKHODKO, OLGA · 2021 to 2023
$210k
Targeting Kinesin-5 Activity for treatment of Alzheimer's diseaseF99NS115330 · NINDS · UNIVERSITY OF COLORADO DENVER · PI LUCERO, ESTEBAN M · 2019 to 2021
$73k
NIA NIH HHS F32 AG071073NIA NIH HHS K01 AG049164NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG059716NIA NIH HHS R01 AG061518NIA NIH HHS U01 AG061356NINDS NIH HHS F99 NS115330NINDS NIH HHS R01 NS110383
6 · The paper itself

Abstract

Previously, we found that amyloid-beta (Aβ) competitively inhibits the kinesin motor protein KIF11 (Kinesin-5/Eg5), leading to defects in the microtubule network and in neurotransmitter and neurotrophin receptor localization and function. These biochemical and cell biological mechanisms for Aβ-induced neuronal dysfunction may underlie learning and memory defects in Alzheimer's disease (AD). Here, we show that KIF11 overexpression rescues Aβ-mediated decreases in dendritic spine density in cultured neurons and in long-term potentiation in hippocampal slices. Furthermore,

Indexed as

Cell biologyCellular neurosciencePathophysiology

Identifiers

PMID36304124
PMCPMC9593841
OpenAlexW4303444588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.